Ivabradina Bluesar

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradina Bluesar (Ivabradine)

Q: What conditions is Ivabradina Bluesar used for?

Ivabradina Bluesar contains ivabradine, which is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction. In both conditions the drug works by lowering heart rate, helping to reduce chest pain episodes and improve heart‑failure symptoms.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the spontaneous depolarisation rate slows, leading to a reduction in heart rate without decreasing the strength of cardiac contraction.

Q: What is the usual dose of Ivabradina Bluesar?

The dose of Ivabradina Bluesar is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Dosage adjustments are made according to therapeutic goals and any observed side effects.

Q: Is Ivabradina Bluesar safe during pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

Q: How do I order Ivabradina Bluesar from GNH India?

To request Ivabradina Bluesar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting blood pressure or myocardial contractility. Beta‑blockers act on adrenergic receptors and can also reduce blood pressure, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Q: What are the recommended storage conditions for Ivabradina Bluesar?

Store Ivabradina Bluesar at ambient temperature, below 25 °C, in the original packaging. Keep the tablets away from moisture, direct sunlight and excessive heat to maintain product stability.

Q: How is Ivabradina Bluesar administered?

Ivabradina Bluesar is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed or chewed unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with ivabradine?

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances such as persistent phosphenes. Patients should be monitored for these events, especially when starting therapy or adjusting the dose.

Q: Who should not use Ivabradina Bluesar?

Ivabradina Bluesar is contraindicated in patients with a resting heart rate below 60 bpm, those with sick sinus syndrome, second‑ or third‑degree atrioventricular block, or severe hepatic impairment. It should also be avoided in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.

Ivabradine, the active ingredient in Ivabradina Bluesar, is an If channel inhibitor presented as a tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in adults. The product is manufactured under EU GMP guidelines and is available for export to multiple regions.
GNH India supplies Ivabradina Bluesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements for safe distribution.

Manufacturer / TM Owner

Bluepharma Genéricos - Comércio De Medicamentos, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine is used to manage conditions related to myocardial oxygen demand and heart rate control.
Chronic stable angina pectoris: reduces frequency of angina attacks and improves exercise tolerance.
Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalisation.
Ischemic heart disease: helps relieve angina symptoms as part of comprehensive therapy.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows spontaneous depolarisation. By reducing this pacemaker current, the drug lowers heart rate without affecting myocardial contractility or blood pressure, thereby decreasing myocardial oxygen consumption.

Side Effects

Adverse reactions may occur with ivabradine therapy.

Common Side Effects

Visual disturbances (phosphenes) especially at the start of treatment.
Bradycardia (resting heart rate <60 bpm).
Headache.
Dizziness.
Fatigue.
Nausea.

Serious or Rare Side Effects

Severe bradycardia leading to syncope.
Atrial fibrillation.
Symptomatic hypotension.
Persistent visual impairment.
Elevated liver enzymes.
Symptomatic heart block.

Precautions & Warnings

Before prescribing ivabradine, consider the following precautions.

Monitor heart rate: avoid use if resting HR is below 60 bpm.
Assess hepatic function: use with caution in severe impairment.
Evaluate for sick sinus syndrome or atrioventricular block: contraindicated.
Review concomitant beta‑blocker therapy to prevent excessive bradycardia.
Pregnancy and lactation: safety unknown; use only if clearly needed.
Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with several medicines; monitor accordingly.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce efficacy.
Other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of severe bradycardia.

Moderate Interactions (Monitor Closely)

Verapamil or diltiazem: may raise ivabradine concentrations.
Antacids containing aluminium or magnesium: can decrease absorption.
Simvastatin: may increase risk of visual disturbances.

Frequently Asked Questions

Ivabradina Bluesar contains ivabradine, which is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction. In both conditions the drug works by lowering heart rate, helping to reduce chest pain episodes and improve heart‑failure symptoms.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the spontaneous depolarisation rate slows, leading to a reduction in heart rate without decreasing the strength of cardiac contraction.

The dose of Ivabradina Bluesar is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Dosage adjustments are made according to therapeutic goals and any observed side effects.

Safety data for ivabradine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To request Ivabradina Bluesar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting blood pressure or myocardial contractility. Beta‑blockers act on adrenergic receptors and can also reduce blood pressure, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Store Ivabradina Bluesar at ambient temperature, below 25 °C, in the original packaging. Keep the tablets away from moisture, direct sunlight and excessive heat to maintain product stability.

Ivabradina Bluesar is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances such as persistent phosphenes. Patients should be monitored for these events, especially when starting therapy or adjusting the dose.

Ivabradina Bluesar is contraindicated in patients with a resting heart rate below 60 bpm, those with sick sinus syndrome, second‑ or third‑degree atrioventricular block, or severe hepatic impairment. It should also be avoided in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.